安大略省多伦多 --（Newsfile Corp. -2026 年 1 月 23 日）- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)（&#34; Cardiol&#34; 或 &#34; 公司&#34;），是一家专注于推进心脏病抗炎和抗纤维化疗法开发的后期生命科学公司，今天宣布已完成其之前宣布的单位私募配售（&#34;单位&#34;）(&#34;发行&#34;），包括超额配售选择权的完全行使。Canaccord Genuity Corp.（&#34;承销商&#34;）作为本次发行的唯一承销商和唯一账簿管理人。根据本次发行，公司共发行了 11,423,078 个单位，每个单位的价格为 1.30 美元，总毛收益为 1485 万美元，其中包括承销商对超额配售选择权的完全行使。
每个单位由一股公司 A 类普通股（每股称为&#34;普通股&#34;）和半个普通股认购权证（每个称为&#34;认购权证&#34;）组成。每个完整的认购权证使持有人有权在认购权证发行之日起 24 个月内以每个认购权证的行使价格 1.75 美元购买一股普通股（每股称为&#34;认购权证股份&#34;）。与本次发行相关，公司向承销商支付了相当于本次发行总毛收益 6% 的现金佣金。
公司计划将融资的净收益用于推进其研究和临床开发项目，以及一般和行政费用、营运资金和其他费用。
本次发行是通过根据国家法规第 45-106 号 - 招股说明书豁免（&#34;NI 45-106&#34;）第 5A 部分进行的私募配售，依据 CSA 协调的第 45-935 号通用命令 - 上市发行人融资豁免的某些条件的豁免（&#34;上市发行人融资豁免&#34;）向加拿大各省和地区（魁北克省除外）的合格投资者进行。承销商有权在加拿大和美国以外的某些司法管辖区提供单位出售，前提是理解在这些其他司法管辖区不会产生招股说明书备案或类似义务、持续报告要求或必要的监管或政府批准。根据适用的加拿大证券法，依据上市发行人融资豁免发行的单位不受在加拿大转售限制。
本新闻稿不构成在美国出售证券或征求购买证券的要约，也不应在任何法律禁止此类要约、征求或销售的司法管辖区进行证券销售。所提供的证券尚未，也不会根据 1933 年美国证券法（&#34;1933 年法&#34;）或任何美国州证券法进行注册，并且不得在&#34;美国&#34;或&#34;美国人士&#34;（如 1933 年法第 S 条中定义的术语）中提供或出售，除非根据 1933 年法及适用的州证券法进行注册，或符合豁免要求。
关于 Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) 是一家专注于推进心脏病抗炎和抗纤维化疗法开发的后期生命科学公司。公司的主要小分子药物候选者 CardiolRx™，调节炎症小体通路的激活，这是一个已知在与心包炎、心肌炎和心力衰竭相关的炎症和纤维化的发展和进展中发挥重要作用的细胞内过程。
MAVERIC 项目正在评估 CardiolRx™用于治疗复发性心包炎，这是一种与严重胸痛、呼吸急促和疲劳等症状相关的心包炎症性疾病，可能导致身体限制、生活质量下降、急诊就诊和住院。该项目包括已完成的 II 期 MAvERIC-Pilot 研究（NCT05494788）和正在进行的关键 III 期 MAVERIC 试验（NCT06708299）。美国 FDA 已授予 CardiolRx™用于治疗心包炎，包括复发性心包炎的孤儿药资格。
ARCHER 项目也在研究 CardiolRx™，特别是在急性心肌炎中——这是年轻人急性和暴发性心力衰竭的重要原因，也是 35 岁以下人群中突发性心脏死亡的主要原因。该项目包括已完成的 II 期 ARCHER 研究（NCT05180240），评估了 CardiolRx™在该患者群体中的安全性、耐受性和有效性。
公司还在开发 CRD-38，这是一种新型的皮下给药药物制剂，旨在治疗炎症性心脏病，包括心力衰竭——这是发达国家死亡和住院的主要原因，相关的医疗费用在美国每年超过 300 亿美元。
有关 Cardiol Therapeutics 的更多信息，请访问 cardiolrx.com。
关于前瞻性信息的警示声明：
本新闻稿包含适用证券法意义上的 “前瞻性信息”。除历史事实陈述外，所有涉及 Cardiol 认为、期望或预期将、可能、能够或可能发生的活动、事件或发展的陈述均为 “前瞻性信息”。此处包含的前瞻性信息可能包括但不限于关于公司对募集资金使用及在完成发行后可用资金使用的预期、公司专注于开发用于治疗心脏病的抗炎和抗纤维化疗法的计划、公司计划进行的临床研究及相关活动和时间表，包括公司计划完成与 CardiolRx™的复发性心包炎的第三阶段研究、公司计划推进 CRD-38 的开发，这是一种用于治疗炎症性心脏病（包括心力衰竭）的新型皮下制剂，包括通过启动首次人体临床评估。此处包含的前瞻性信息反映了 Cardiol 基于当前可用信息的当前预期或信念，并基于某些假设，同时也受到各种已知和未知风险、不确定性及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息所表达或暗示的未来结果、表现或成就有实质性差异，并且不应被视为未来表现的保证。这些风险和不确定性及其他因素包括在公司向加拿大证券管理机构提交的年度信息表中提到的风险和不确定性，该信息表可在 SEDAR+ 网站（sedarplus.ca）上获取，以及与产品商业化和临床研究相关的风险和不确定性。这些假设、风险、不确定性及其他因素应仔细考虑，投资者不应对前瞻性信息过度依赖，且该信息可能不适用于其他目的。任何前瞻性信息仅在本新闻稿发布之日有效，除非适用证券法要求，Cardiol 不承担更新或修订此类前瞻性信息的意图或义务，无论是由于新信息、未来事件或结果，还是其他原因。投资者应谨慎对待这些前瞻性陈述。
如需更多信息，请联系：
Investor.relations@cardiolrx.com
<img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5704/281332_4a511521844aeb7c_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5704/281332_4a511521844aeb7c_logo.jpg"/>
要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/281332
<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281332/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281332/375"/>

Cardiol Therapeutics Inc. 成功完成了一项单位的私募配售，筹集了 1485 万美元的总收入。此次发行包括超额配售选择权的全部行使，共售出 11,423,078 个单位，每个单位价格为 1.30 美元。每个单位由一股普通股和半个认股权证组成，允许以 1.75 美元的价格购买额外的股票。这笔资金将用于研究、临床开发和一般开支。此次发行是在加拿大证券法规下进行的，未经过适当注册的美国投资者无法参与

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (&#34; Cardiol&#34; or the &#34; Company&#34;), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the &#34;Units&#34;) of the Company (the &#34;Offering&#34;), including the full exercise of the over-allotment option. Canaccord Genuity Corp. (the &#34;Underwriter&#34;) acted as sole underwriter and sole bookrunner for the Offering. Pursuant to the Offering, the Company issued an aggregate of 11,423,078 Units at a price of $1.30 per Unit for aggregate gross proceeds of $14.85 million, which includes the full exercise by the Underwriter of the over-allotment option.
<div class="lb-trans">安大略省多伦多 --（Newsfile Corp. -2026 年 1 月 23 日）- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)（&#34; Cardiol&#34; 或 &#34; 公司&#34;），是一家专注于推进心脏病抗炎和抗纤维化疗法开发的后期生命科学公司，今天宣布已完成其之前宣布的单位私募配售（&#34;单位&#34;）(&#34;发行&#34;），包括超额配售选择权的完全行使。Canaccord Genuity Corp.（&#34;承销商&#34;）作为本次发行的唯一承销商和唯一账簿管理人。根据本次发行，公司共发行了 11,423,078 个单位，每个单位的价格为 1.30 美元，总毛收益为 1485 万美元，其中包括承销商对超额配售选择权的完全行使。
</div>Each Unit consists of one Class A common share of the Company (each, a &#34;Common Share&#34;) and one-half of one Common Share purchase warrant (each, a &#34;Warrant&#34;). Each whole Warrant entitles the holder thereof to purchase one Common Share (each, a &#34;Warrant Share&#34;) at an exercise price of $1.75 per Warrant Share at any time for a period of 24 months from the date of issuance of the Warrants. In connection with the Offering, the Company paid the Underwriter a cash commission equal to 6% of the aggregate gross proceeds of the Offering.
<div class="lb-trans">每个单位由一股公司 A 类普通股（每股称为&#34;普通股&#34;）和半个普通股认购权证（每个称为&#34;认购权证&#34;）组成。每个完整的认购权证使持有人有权在认购权证发行之日起 24 个月内以每个认购权证的行使价格 1.75 美元购买一股普通股（每股称为&#34;认购权证股份&#34;）。与本次发行相关，公司向承销商支付了相当于本次发行总毛收益 6% 的现金佣金。
</div>The Company intends to use the net proceeds of the financing to advance its research and clinical development programs and for general and administrative expenses, working capital, and other expenses.
<div class="lb-trans">公司计划将融资的净收益用于推进其研究和临床开发项目，以及一般和行政费用、营运资金和其他费用。
</div>The Offering was completed by way of a private placement pursuant to National Instrument 45-106 - Prospectus Exemptions (&#34;NI 45-106&#34;) under Part 5A, as amended by CSA Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the &#34;Listed Issuer Financing Exemption&#34;) to qualified investors in each of the provinces and territories of Canada (other than Quebec). The Underwriter was entitled to offer the Units for sale in certain jurisdictions outside of Canada and the United States, provided it is understood that no prospectus filing or comparable obligation, ongoing reporting requirement or requisite regulatory or governmental approval arises in such other jurisdictions. The Units issued under the Listed Issuer Financing Exemption are not subject to resale restrictions in Canada pursuant to applicable Canadian securities laws.
<div class="lb-trans">本次发行是通过根据国家法规第 45-106 号 - 招股说明书豁免（&#34;NI 45-106&#34;）第 5A 部分进行的私募配售，依据 CSA 协调的第 45-935 号通用命令 - 上市发行人融资豁免的某些条件的豁免（&#34;上市发行人融资豁免&#34;）向加拿大各省和地区（魁北克省除外）的合格投资者进行。承销商有权在加拿大和美国以外的某些司法管辖区提供单位出售，前提是理解在这些其他司法管辖区不会产生招股说明书备案或类似义务、持续报告要求或必要的监管或政府批准。根据适用的加拿大证券法，依据上市发行人融资豁免发行的单位不受在加拿大转售限制。
</div>THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE SECURITIES BEING OFFERED HAVE NOT BEEN, NOR WILL THEY BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE &#34;1933 ACT&#34;), OR UNDER ANY U.S. STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE &#34;UNITED STATES&#34; OR TO &#34;U.S. PERSONS&#34; (AS SUCH TERMS ARE DEFINED IN REGULATION S UNDER THE 1933 ACT) ABSENT REGISTRATION UNDER THE 1933 ACT, AND APPLICABLE STATE SECURITIES LAWS, OR COMPLIANCE WITH THE REQUIREMENTS OF EXEMPTIONS THEREFROM.
<div class="lb-trans">本新闻稿不构成在美国出售证券或征求购买证券的要约，也不应在任何法律禁止此类要约、征求或销售的司法管辖区进行证券销售。所提供的证券尚未，也不会根据 1933 年美国证券法（&#34;1933 年法&#34;）或任何美国州证券法进行注册，并且不得在&#34;美国&#34;或&#34;美国人士&#34;（如 1933 年法第 S 条中定义的术语）中提供或出售，除非根据 1933 年法及适用的州证券法进行注册，或符合豁免要求。
</div>About Cardiol Therapeutics
<div class="lb-trans">关于 Cardiol Therapeutics
</div>Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
<div class="lb-trans">Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) 是一家专注于推进心脏病抗炎和抗纤维化疗法开发的后期生命科学公司。公司的主要小分子药物候选者 CardiolRx™，调节炎症小体通路的激活，这是一个已知在与心包炎、心肌炎和心力衰竭相关的炎症和纤维化的发展和进展中发挥重要作用的细胞内过程。
</div>The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.
<div class="lb-trans">MAVERIC 项目正在评估 CardiolRx™用于治疗复发性心包炎，这是一种与严重胸痛、呼吸急促和疲劳等症状相关的心包炎症性疾病，可能导致身体限制、生活质量下降、急诊就诊和住院。该项目包括已完成的 II 期 MAvERIC-Pilot 研究（NCT05494788）和正在进行的关键 III 期 MAVERIC 试验（NCT06708299）。美国 FDA 已授予 CardiolRx™用于治疗心包炎，包括复发性心包炎的孤儿药资格。
</div>The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis-an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
<div class="lb-trans">ARCHER 项目也在研究 CardiolRx™，特别是在急性心肌炎中——这是年轻人急性和暴发性心力衰竭的重要原因，也是 35 岁以下人群中突发性心脏死亡的主要原因。该项目包括已完成的 II 期 ARCHER 研究（NCT05180240），评估了 CardiolRx™在该患者群体中的安全性、耐受性和有效性。
</div>The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.
<div class="lb-trans">公司还在开发 CRD-38，这是一种新型的皮下给药药物制剂，旨在治疗炎症性心脏病，包括心力衰竭——这是发达国家死亡和住院的主要原因，相关的医疗费用在美国每年超过 300 亿美元。
</div>For more information about Cardiol Therapeutics, please visit cardiolrx.com.
<div class="lb-trans">有关 Cardiol Therapeutics 的更多信息，请访问 cardiolrx.com。
</div>Cautionary statement regarding forward-looking information:
<div class="lb-trans">关于前瞻性信息的警示声明：
</div>This news release contains &#34;forward-looking information&#34; within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are &#34;forward-looking information&#34;. Forward-looking information contained herein may include, but is not limited to statements regarding the Company's expectations with respect to the use of proceeds and the use of the available funds following completion of the Offering, Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™, the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of the first-in-human clinical evaluation. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators, available on SEDAR+ at sedarplus.ca, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.
<div class="lb-trans">本新闻稿包含适用证券法意义上的 “前瞻性信息”。除历史事实陈述外，所有涉及 Cardiol 认为、期望或预期将、可能、能够或可能发生的活动、事件或发展的陈述均为 “前瞻性信息”。此处包含的前瞻性信息可能包括但不限于关于公司对募集资金使用及在完成发行后可用资金使用的预期、公司专注于开发用于治疗心脏病的抗炎和抗纤维化疗法的计划、公司计划进行的临床研究及相关活动和时间表，包括公司计划完成与 CardiolRx™的复发性心包炎的第三阶段研究、公司计划推进 CRD-38 的开发，这是一种用于治疗炎症性心脏病（包括心力衰竭）的新型皮下制剂，包括通过启动首次人体临床评估。此处包含的前瞻性信息反映了 Cardiol 基于当前可用信息的当前预期或信念，并基于某些假设，同时也受到各种已知和未知风险、不确定性及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息所表达或暗示的未来结果、表现或成就有实质性差异，并且不应被视为未来表现的保证。这些风险和不确定性及其他因素包括在公司向加拿大证券管理机构提交的年度信息表中提到的风险和不确定性，该信息表可在 SEDAR+ 网站（sedarplus.ca）上获取，以及与产品商业化和临床研究相关的风险和不确定性。这些假设、风险、不确定性及其他因素应仔细考虑，投资者不应对前瞻性信息过度依赖，且该信息可能不适用于其他目的。任何前瞻性信息仅在本新闻稿发布之日有效，除非适用证券法要求，Cardiol 不承担更新或修订此类前瞻性信息的意图或义务，无论是由于新信息、未来事件或结果，还是其他原因。投资者应谨慎对待这些前瞻性陈述。
</div>For further information, please contact:
<div class="lb-trans">如需更多信息，请联系：
</div>Investor.relations@cardiolrx.com
<div class="lb-trans">Investor.relations@cardiolrx.com
</div><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5704/281332_4a511521844aeb7c_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/5704/281332_4a511521844aeb7c_logo.jpg"/>
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281332
<div class="lb-trans">要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/281332
</div><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281332/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/281332/375"/>

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million | CRDL Stock News

StockTitan

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

标普生物技术 3 倍做空 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

美国制药 ETF - iShares

Cardiol Therapeutics

Turn Therapeutics

Channel Therapeutics

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

Cardiol Therapeutics 宣布完成包销融资，并全额行使超额配售选择权，获得 1485 万美元的毛收益 | CRDL 股票新闻